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Overcoming Resistance: 
A Review on Chemotherapy Resistance in Cancer 
Andrea Fjelstul 
Department of Biomedical Sciences, Iowa State University, Ames, Iowa, USA 
 
Abstract 
Cancer has been around for as long as history can tell, and it is very prevalent in the 
United States today, affecting about one-third of people (The American Cancer Society 
Medical and Editorial Content Team, 2018). Traditionally, chemotherapy has been the 
method of treatment for cancer, inducing apoptosis and slowing down replication rate. 
Although successful in the past, cancer is becoming more and more resistant to 
chemotherapy treatment due to its ever-evolving nature. There are many mechanisms 
by which cancer evades chemotherapy, but four of the most common methods will be 
highlighted in this paper. Cancer cells are able to continue past cell cycle checkpoints 
and avoid apoptosis, which chemotherapy attempts to induce. The tumor 
microenvironment also plays a vital role in chemotherapy resistance, as does the 
presence of cancer stem cells. With all of these methods of evasion, there is room for 
new developments to treat cancer, including the use of CAR T-cell therapy, the use of 
ctDNA technology for earlier detection of resistance, optimizing doses, scheduling, and 
combination drugs, and implementing local delivery through ADCs. Although there are 
seemingly promising future therapeutics, further research must be conducted in order to 
find more solutions to resistance that specifically target chemoresistance. 
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Introduction 
Cancer has been around for as long as humans are able to tell through recorded history. 
Some of the oldest findings of cancer have been in fossilized bone tumors, in human 
mummies of ancient Egypt, and in ancient manuscripts. An ancient Egyptian textbook on 
trauma surgery has the oldest written description of cancer. The text is from 3000 BC and 
describes different types of tumors of the breast. This was prior to the use of the word 
‘cancer.’ The term was coined first by Hippocrates (460-370 BC), the Greek physician 
who is said to be the father of medicine. Hippocrates used the terms ‘carcinos’ and 
‘carcinomas’—words that mean crab in Greek. It is hypothesized that the use of a word 
meaning crab was due to the spreading of cancer resembling the shape of a crab. 
Carcinoma is now used to define a cancer that arises in the epithelial tissue of the skin or 
lining of the internal organs. The Roman physician Celsus (28-50 BC) translated carcino 
to cancer, which is the Latin word for crab, giving the widely used term today. Additionally, 
the Greek physician Galen (130-200 AD) used the word oncos in working with cancer, 
which is Greek for swelling. Today, this has evolved into the use of the term oncology, 
which is the study and treatment of tumors (The American Cancer Society Medical and 
Editorial Content Team, 2018). 
 
Cancer is the second leading cause of death in the United States, and about one-third of 
all people in the U.S. will develop cancer in their lifetimes (The American Cancer Society 
Medical and Editorial Content Team, 2018). The first known method to treat cancer was 
by surgery to remove the tumors. When this didn’t prove effective, radiotherapy was used. 
Eventually, and, traditionally, chemotherapy has been the best way to treat cancer, but 
resistance to chemotherapy has proven to be a large limiting factor in producing cures in 
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patients as of recent. The first solution to fight against this resistance was the use of 
polychemotherapy, which is the use of several different chemotherapy drugs that do not 
overlap in their mechanism. This method worked well in lymphoma, breast cancer, and 
testicular cancer (Vasan, 2019). After about 50 years of polychemotherapy working 
tremendously when in combination with surgery and radiotherapy, its efficacy plateaued. 
Targeted therapies seemed to be the next-best approach. With the understanding of the 
biological properties behind cancer came therapies with great efficacy. This, too, has 
seen problems in cancer evolving to promote its resistance. Following the same trend, 
immunological approaches using monoclonal antibodies that turn off the checkpoints of 
the adaptive immune system, and have proved effective, are now faced with resistance 
as well (Vasan, 2019).  
 
 
Figure 1: A timeline of the evolution of cancer treatments 
 
 
Chemotherapy resistance can be broken down into two main categories—acquired and 
intrinsic. Intrinsic resistance specifies that resistance factors existed in the tumor cells 
prior to the administration of chemotherapy drugs, rendering them ineffective. Acquired 
resistance, on the other hand, typically develops during treatments. In this case, tumors 
respond to treatment originally, but mutations and adaptive responses take over, allowing 











Additionally, tumors have a high amount of molecular heterogeneity, meaning that 
resistance can come about through selection of an originally small number of resistant 
cells (Holohan, 2013). 
 
The size of tumors, in addition to the rate of tumor growth and changes in growth kinetics, 
play critical roles in responses to therapy and resistance as well (Vasan, 2019). Tumor 
heterogeneity is one of the most widely conceptualized methods of chemotherapy 
resistance. The processes that control tumor growth and survival are ever evolving and 
none is like the others, creating resistance mechanisms (Keller L. &., 2019). Exogenous 
exposures, internal environment, and the cancer therapies themselves can all lead to 
genomic instability, which is a driver for cancer to persist (Vasan, 2019). 
 
Cancer is a dynamic, complex, ever-evolving problem, and the effectiveness of 
chemotherapy is widely limited by drug resistance. Here, I will attempt to explain the many 
ways that cancer is able to evade drug therapies, including the mechanisms used in 
evading cell repair and continuing past cell cycle checkpoints, how cancerous cells avoid 
apoptosis, the role of the tumor microenvironment in resistance, and how the presence 
of cancer stem cells help cancerous cells evade drug therapy. I will end by discussing 
some promising future therapeutics, although more research must be done in order to 
fully understand chemoresistance. 
 
Evading Cell Repair 
As stated previously, cancer is able to resist chemotherapy by four main mechanisms. 
The first of which is by evasion of cell repair. The cell cycle consists of the G1, S, G2, and 
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M phases. The G1 phase consists of preparing for synthesis, while the S phase is where 
DNA synthesis and chromosome duplication actually occur. Following the S phase, 
preparation for division occurs during the G2 phase. Mitosis, the division into two daughter 
cells, follows. G1, S, and G2 make up interphase in cells that are dividing continuously. 
Checkpoints exist before both the S phase and the M phase. In a typical cell, the cell 
cycle will arrest at these two points if DNA damage is present. At the first checkpoint, 
Retinoblastoma (Rb) acts as a brake, keeping the cycle in the G1 phase. Rb does this by 
inhibiting the genes that are necessary for entry into the S phase. When CDKs (cyclin-
dependent kinases) are phosphorylated, the cycle can continue. If DNA damage is 
present, p53 stops the cell cycle here. Cancer has a way of evading these cell cycle 
arrests in order to continually proliferate. 
 
Figure 2: A simple schematic of the cell cycle, including checkpoints 1 and 2, which play 
a role in chemotherapy treatment and in resistance. 
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Traditional chemotherapy works by inducing DNA damage, which causes cell cycle 
arrest. If the damage is not able to be repaired in this arrest, cell death should ensue 
thereafter. Chemotherapy drugs can be cell cycle non-specific, meaning the drugs can 
kill at any point in the cell cycle, or they can be cell cycle-specific, meaning they kill cancer 
cells only during a specific phase in the cell cycle. These drugs induce DNA damage in 
hopes that the cell cycle will arrest and cause the cancerous cells to become apoptotic, 
thus getting rid of the cancer. One common way that cancer cells resist chemotherapy is 
by evading checkpoints—the cells continue throughout the cell cycle, making it past 
checkpoints that should otherwise stop them. This is due to either gain-of-function to 
oncogenes or loss-of-function to tumor suppressor genes. These act by disrupting the 
regulation of cell cycle arrest, such as by causing mutations in the p53 protein, which 
stops the cell cycle if there has been damage. The use of combination drugs, ones that 
both damage DNA and inhibit DNA damage repair, has been used to combat this.  
 
Another mode of resistance in this realm is discussed in a paper by Jia et. al. on 
neoadjuvant endocrine therapy, which has been shown to be a useful treatment in ER-
positive (estrogen receptor-positive) breast cancer patients, but resistance is still 
prevalent. In this study on neoadjuvant endocrine therapy (Jia, 2019), it was determined 
that RAD51 recombinase could potentially be a factor in the resistance. RAD51 is a major 
protein involved in homologous recombination, and it was found to interact with BRCA2. 
The enzyme encoded by RAD51 is involved in the repair of DNA double stranded breaks. 
Overexpression of RAD51 correlated with BRCA2 hypermethylation, resistance to 
therapy, and poor survival in patients (Jia, 2019). This ties into evasion of cell repair, 
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because dysregulation of the RAD51 gene is known to promote cell division and/or 
repress cell cycle arrest controls or apoptosis (Jia, 2019). 
 
Another study that discusses this mechanism of resistance was conducted by Wang et. 
al. and looked at the LRH1 protein and the mismatch repair system. The mismatch repair 
system (MMR) is responsible for finding and repairing errors (insertions, deletions, 
incorrect bases) that occur during DNA replication. LRH1 (liver receptor homolog-1) has 
been shown to enhance tumor proliferation and development in human breast cancer 
(Wang, 2018). In this study, it was shown that knockout of LRH1 dramatically decreased 
non-homologous end-joining-mediated double-strand break repair efficiencies (Wang, 
2018). In patients who had early recurrence in breast cancer, there were elevated levels 
of LRH1. This study (Wang, 2018) showed that LRH1 activates MDC1, a mediator of DNA 
damage checkpoint one. This activation, then, is able to further reduce the effects of DNA 
damage caused by chemotherapy. This reduction in DNA damage then causes the 




The second major mechanism of chemotherapy resistance includes that of avoidance of 
apoptosis. In the cell cycle, when DNA damage cannot be repaired, the cells undergo 
apoptosis—programmed cell death. In this case, the cell dies, the chromatin condense, 
the cytoplasm shrinks, and the membrane blebs. In cancer, this system fails. There are 
two pathways of apoptosis, the extrinsic pathway (death receptor-initiated pathway) and 
the intrinsic pathway (mitochondrial pathway). The extrinsic pathway is triggered by 
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receptor-ligand interactions, such as with the TNF (tumor necrosis factor) receptor family 
and the Fas family. This pathway activates caspase 8. The intrinsic pathway is initiated 
by injuries that cause mitochondrial permeability, which causes release of pro-apoptotic 
cytochrome c. This activates caspase 9. Caspase 8 and 9 both act on caspase 3, which 
initiates the effector stage of apoptosis, consisting of cleavage and inactivation of 
enzymes and structural constituents, fragmentation of genomic DNA, cytoskeletal 
breakdown, and the formation of apoptotic bodies. 
 
 
Figure 3: A diagram of the two apoptotic pathways. The red line in the intrinsic pathway 
indicates inhibition. The caspase involved in the intrinsic is caspase 9, the extrinsic is 




The literature (Holohan, 2013) states that cancer cells are typically ‘addicted’ to a few 
anti-apoptotic proteins that promote their survival. The intrinsic, or mitochondrial, pathway 
relies on the pro- and anti-apoptotic BCL-2 family, and its members are the most 
prominent in those that cancer cells use to stay alive. Overexpression of the anti-apoptotic 
BCL-2 family members has been shown to cause chemotherapy resistance by blocking 
the intrinsic apoptotic pathway. This is indicated in Figure 3 as the red inhibition arrow. 
Additionally, IAPs, or inhibitor of apoptosis proteins, have been linked to chemoresistance 
in patients (Holohan, 2013). IAPs act by blocking caspase 3, the caspase that causes the 
executioner phase. The executioner phase, as indicated above, causes the mechanisms 
of apoptosis, so, therefore, an abundance of them can cause avoidance of apoptosis. 
Finally, one more important player in avoiding apoptosis, is the caspase 8 inhibitor FLIP 
(Holohan, 2013). Caspase 8 is activated via the death receptor, or extrinsic, apoptotic 
pathway, which is shown on the right side of Figure 3. Inhibition of this caspase, then, 
would further inhibit the extrinsic apoptotic pathway from ensuing.   
 
In a study by Arumugam et. al., overexpression of the GHR (growth hormone receptor) 
and its presence in ER-negative breast cancer was studied (Arumugam, 2019). In this 
study, the concentration of GHR was directly correlated to chemoresistance, metastasis, 
and tumor progression. Inhibiting GHR was linked to reducing the AKT/mTOR pathway. 
This intracellular signaling pathway is important in regulating cell metabolism, growth, 
proliferation, and survival. Inhibiting GHR in ER-negative breast cancer cells led to more 
apoptosis in the study, indicating that GHR plays a role in controlling the AKT/mTOR 
pathway, which then can impact chemoresistance. On the other hand, when GHR was 
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upregulated in the study, chemoresistance was also upregulated. This is yet another 
example of an upregulation in cancer cells that causes avoidance of apoptosis. 
 
Tumor Microenvironment 
The tumor microenvironment and the immune system have a large influence on the way 
tumors behave. In tumors that are solid, the microenvironment is composed of many 
cellular parts, including: the extracellular matrix, cancer-associated fibroblasts, immune 
and inflammatory cells, and blood vessels (Holohan, 2013). Recently, there has been 
much research conducted that focuses on understanding the immune system in the tumor 
microenvironment. Resistance due to the microenvironment has, in part, to deal with 
preventing immune clearance of tumor cells, causing a burden on drug absorption and 
prompting paracrine growth factors to signal cancer growth (Vasan, 2019). 
 
Figure 4: A schematic of cellular components making up the tumor microenvironment, 
including immune cells and stromal cells (Cui, 2016). 
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Additionally, the microenvironment provides protection for cancer cells to hide from 
cytotoxic agents. This is another way that cancer cells can evade apoptosis and acquire 
resistance to treatments. Integrins, cell surface adhesion molecules that connect cells to 
the extracellular matrix, play a vital role in resistance. Integrin expression is altered in 
tumor cells, and higher expression leads to increased cancer cell survival and drug 
resistance. Adhesion to the ECM via integrins has been shown to alter responses to 
chemotherapy in cancer by inhibiting apoptosis and altering drug targets (Holohan, 2013). 
Cytokines and growth factors play parts in resistance as well. These are able to maintain 
activation of pro-survival pathways, even in the presence of chemotherapy. This, then, 
relates back to avoidance of apoptosis and evasion of the cell cycle checkpoints. 
 
In addition, spatial gradients of cancer cells within tumors due to the microenvironment 
can prevent enough blood flow, which can create a pro-tumorigenic hypoxic environment. 
This decreases the effective exposure of a tumor to drugs (Vasan, 2019). By similar 
mechanisms, cancer cells may take refuge in anatomical spaces where administered 
drugs are unable to reach them. One example of this would be cells colonizing in the 
central nervous system, allowing safety from drugs by the blood brain barrier.  
 
The tumor microenvironment plays a vital role in hindrance to checkpoint inhibitors. 
Specifically, the regulatory T cells, myeloid-derived suppressor cells, tumor-associated 
macrophages, cytokines, and chemokines induce this inhibition (Vasan, 2019). With this 
hindrance, cancer cells are able to progress through the cell cycle, even with damage, as 
noted above. These parts of the tumor microenvironment can all inhibit immune-mediated 
and anti-tumor effects. 
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Finally, the epithelial-mesenchymal transition (EMT) can play a role in chemotherapy 
resistance in regard to tumor microenvironment. The EMT is the process in which tumor 
cells lose epithelial features (E-cadherin expression, epithelial cell junctions, etc.), and 
then develop mesenchymal characteristics. Epithelial cells lose their cell polarity and cell-
cell adhesion and gain migratory and invasive properties to become mesenchymal stem 
cells. Due to this ability of the tumor cells to be in mixed states of epithelial and 
mesenchymal, the EMT has been linked to metastasis, but also to drug resistance 
(Sauvage, 2019). 
 
Cancer Stem Cells 
The final mechanism by which cancer is able to avoid chemotherapy that will be discussed 
in this paper is that of the role of cancer stem cells.  
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Figure 5: The difference between normal stem cells and cancer stem cells. On the left, it 
is seen that normal stem cells come from a variety of tissues, and that they have 
indefinite division through self-renewal and generation of differentiated cells under 
appropriate conditions. On the right, adult stem cells can undergo malignant 
transformation after cumulative genetic alterations caused by carcinogens, generating 
CSCs. These CSCs retain the biological properties of the self-renewal and generation of 
differentiated cancer cells, leading to cancer development and further metastasis 
(Rodini, 2017).  
 
Cancer stem cells have been linked to acquired chemotherapy resistance in many 
different types of cancers. Cancer stem cells (CSCs) have many properties that other 
cells lack, allowing them to evade chemotherapy. CSCs have the ability to self-renew, 
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promoting the recurrence of tumors after chemotherapy. Other studies have shown that 
CSCs do not have differentiation markers (Vidal, 2014). The maintenance of the non-
dividing state during the cell cycle while still having the ability to reenter the proliferative 
part of the cell cycle is called quiescence. This is a very important feature of CSCs, 
indicating that many of them can lie “dormant” and appear as if the cancer is gone in 
patients but can jump right back into the proliferative stage at any point (Vidal, 2014). 
 
DNA methylation, RNA-mediated targeting, and histone modification are epigenetic 
mechanisms by which gene expression can be altered. They also regulate many other 
important biological processes in cancer. CSCs are suspected to be genetically identical 
to their differentiated cells, with epigenetic regulators fundamental to the CSC state (Vidal, 
2014). As was already discussed previously, cancer cells resist chemotherapy by evading 
apoptosis and promoting cell survival. It is believed that cancer stem cells play a pivotal 
role in this resistance. They have been shown to deregulate mitochondrial proteins, 
decrease DR5 (death receptor 5) expression, interact in cytokine signaling, and develop 
signaling pathways that promote survival (Vidal, 2014). Additionally, it has been 
discovered in recent studies that CSCs have distinct metabolic activities. This can be 
linked to the uncontrolled proliferation of cancer cells due to problems with the regulation 
of metabolism. Finally, the epithelial mesenchymal transition, can also be important in 
CSC mechanisms to resist chemotherapy. The EMT is an important regulator of the CSC 
phenotype and tumor heterogeneity, which both relate back to resistance mechanisms 
(Shibue T. &., 2017). 
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With all of these mechanisms highlighted, it can be observed that many of the 
mechanisms of chemotherapy resistance in cancer stem cells are the same mechanisms 
responsible for chemotherapy resistance in normal cancer cells, just with a unique 
perspective toward cancer stem cells. 
 
Future Therapeutics 
Chemotherapy resistance is a grand problem that is very prevalent. It occurs by many 
mechanisms, but those mechanisms can mostly fall into four main categories: evading 
cell repair, avoiding apoptosis, factors due to the tumor microenvironment, and the 
presence of cancer stem cells. This list is in no way comprehensive, but hits on the major 
methods known today of chemotherapy resistance. Each of these categories has complex 
mechanisms by which they cause resistance, and each deserves further research into 
how best to deal with resistance moving forward—most importantly, how to avoid it. 
 
Many of the mechanisms of chemotherapy resistance can be targeted by specific 
therapies with the intent of destabilizing these mechanisms. For example, the use of CAR 
T-cell therapy has shown promising preliminary results as a cancer therapy. This therapy 
is a form of immunotherapy that uses specially altered T cells to fight the cancer. In this 
therapy, a sample of a patient’s T Cells are collected and modified to present chimeric 
antigen receptors (CARs) on their surface to aid in therapy. Cancer stem cells can 
specifically be targeted to inhibit their resistance mechanisms as well. Their self-renewal, 
lack of differentiation, and quiescence can be specifically targeted. 
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Tumors are typically detected as being resistant simply through biopsy techniques, but 
more in-depth methods would be able to identify resistance earlier, especially since 
different metastases can have different resistance mechanisms. There is promise in using 
ctDNA technology to also help in this aspect, with the ability to monitor heterogeneity, 
evolution, and response to therapy (Vasan, 2019). Circulating tumor DNA (ctDNA) can 
be detected in the blood, and testing for it can be done to find cancers early (Vasan, 
2019). Circulating tumor DNA is tumor-derived fragmented DNA in the bloodstream. 
Using ctDNA-based methods could provide monitoring of tumors in real-time, allowing 
providers to be able to identify patients at risk of relapse and to aid in the planning of the 
next modes of therapy based on tumor behavior. The use of ctDNA as a screening tool 
is a new idea, so clinical trials and further research must be conducted on its efficacy 
before being implemented. 
 
In the interest of achieving deeper responses to chemotherapy, optimizing doses, 
scheduling, and combination drugs/therapies is vital. These must all be adapted together 
as studies have shown that just increasing dose alone, for example, does not promote 
tumor response to the drug. Another way to increase response would be to implement 
local delivery of chemotherapy—a dose that would be too toxic if delivered systemically, 
but that, when given locally, targets the tumors well. This has been shown to be effective 
through ADCs (antibody-drug conjugates). These are recombinant monoclonal antibodies 
covalently bound to cytotoxic agents through synthetic linkers. ADCs can deliver large 
amounts of the drugs directly to the tumor cells, since the antibodies can be engineered 
to bind to antigens that are exposed on tumor cells with very high affinity (Vasan, 2019). 
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Finally, research needs to be furthered in order to be able to fully understand the 
dependencies of cancer. With this knowledge, therapies would be able to specifically 




Resistance to chemotherapy is the biggest challenge to fighting cancer today. Cancer 
resists chemotherapies by many different mechanisms, some of which have yet to even 
be discovered. Through extensive research, it has been found that cancer resists 
chemotherapy by four main mechanisms, which encompass the main ideas about 
resistance: evading cell cycle checkpoints, avoiding apoptosis, tumor microenvironment 
factors, and the presence of cancer stem cells. These mechanisms all stem from the 
plasticity and heterogeneity of cancer cells. Knowing that each cancer is infinitely unique 
presents many challenges in terms of trying to find a cure for chemotherapy resistance. 
Current research has found a few ideas that seem promising to these problems, including 
the use of ADCs for specific targeting and ctDNA for detection and real-time monitoring. 
Chemotherapy resistance is a complex issue that is very prevalent in the community 
today, and in order to further understand it and put a stop to it, more research must be 
done. 
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